中国实用外科杂志

中国实用外科杂志

• 国外医学动态 • 上一篇    下一篇

2021年“第14届肌少症、恶病质和消耗性疾病协会学术年会”热点内容介绍

刘    皓，王俊杰，谈善军，吴国豪   

  1. 复旦大学附属中山医院普通外科 上海市临床营养研究中心，上海 200032
  • 出版日期:2022-01-01

  • Online:2022-01-01

摘要： 肌少症、恶病质和消耗性疾病协会（SCWD）于2021年12月11—12日以网络虚拟会议的形式召开第14届学术年会。大会从基础科学和临床科学角度对肌少症、恶病质及消耗性疾病的话题展开广泛讨论，主要包括：（1）恶病质与肌少症的发生发展存在多组织器官系统参与的代谢串扰，如脂肪/肌肉串扰、神经/肌肉串扰、肿瘤/脂肪/肌肉串扰、骨髓/中枢神经系统串扰；（2）衰老相关性厌食与恶病质和肌少症关系密切，应加强认识衰老相关性厌食的病因与危害；（3）恶病质和肌少症与心力衰竭之间相互影响，心力衰竭对患者的危害程度不亚于癌症给机体带来的影响，应加强恶病质和肌少症与心力衰竭关系的认识和研究；（4）多种治疗恶病质和肌少症的新方法与新药物被提出，如Anamorelin、Enobosarm、TCMCB07等。药物治疗是未来治疗恶病质主要方式之一；（5）分子作用机制、医学转化研究、临床诊疗标准等是目前恶病质和肌少症基础与临床研究的热点也是难点。

关键词: 恶病质, 肌少症, 消耗性疾病, 临床营养

Abstract: Hot report of the 14th Annual Academic Meeting of the Society of Sarcopenia, Cachexia and Wasting Diseases (SCWD) in 2021        LIU Hao, WANG Jun-jie, TAN Shan-jun, et al.Department of General Surgery, Shanghai Clinical Nutrition Research Center, Zhongshan Hospital,Fudan University, Shanghai 200032, China
Corresponding author: WU Guo-hao, E-mail: prowugh@163.com
Abstract    The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) held the 14th Annual Academic Meeting in the form of an online virtual meeting on December 11-12, 2021. The topic of sarcopenia, cachexia, and wasting diseases was widely discussed from the perspective of basic science and clinical science. The main contents are as follows:（1）The occurrence and development of cachexia and sarcopenia have metabolic crosstalk involving a variety of tissue and organ systems, such as fat-muscle crosstalk, nerve-muscle crosstalk, tumor-fat-muscle crosstalk, and bone marrow-central nervous system crosstalk; （2）Aging-related anorexia is closely related to cachexia and sarcopenia, and the understanding of the etiology and harm of aging-related anorexia should be strengthened; （3）Cachexia and sarcopenia interact with heart failure. Heart failure is no less harmful to patients than the impact of cancer on the body, and the understanding and research of the relationship between cachexia and sarcopenia and heart failure should be strengthened; （4）A variety of new methods and drugs for the treatment of cachexia and sarcopenia have been proposed, such as Anamorelin, Enobosarm, and TCMCB07. Pharmacotherapy is one of the main strategies for the treatment of cachexia in the future; （5）Molecular mechanism, medical translational research, clinical diagnosis and treatment standards are the hotspots and  the challenges of basic research and clinical research on cachexia and sarcopenia.

Key words: cachexia, sarcopenia, wasting disease, clinical nutrition